Vertex Pharmaceuticals stock analysis
Vertex Pharmaceuticals passes 8 of 8 fundamental tests, a score of 10/10. On the daily chart it is in a sideways range, RSI 44, 11% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at $460.11–$542.79 a month from now and $375.35–$665.36 in a year (68% bands). The last two days of news lean bullish (1 positive, 0 negative stories).
Fundamentals 10/10
- Market cap
- $126.7 B
- P/E · forward
- 28.9 · 24.7
- PEG · P/B
- 2.0 · 6.3
- ROE · net margin
- +24% · +35%
- Revenue · earnings growth
- +13% · +8%
- Debt / equity
- 10%
- Dividend · beta
- 0.0% · 0.3
- Next results
- 2 Nov 2026
- ✓ ROE above 15%
- ✓ Net margin above 10%
- ✓ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- sideways · 50d above 200d
- RSI(14)
- 44
- 20 / 50 / 200-day avg
- $510.16 / $522.54 / $475.90
- 20-day breakout
- above $529.89 · below $484.08
- ATR(14)
- $13.24 (2.6% a day)
- 52-week range
- $403.16 – $560.25
- Return 3m · 6m · 1y
- +4% · +13% · +20%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $460.11 – $542.79 (-8% / +9%) |
| 3 mo | $433.10 – $576.63 (-13% / +15%) |
| 6 mo | $408.17 – $611.85 (-18% / +22%) |
| 1 year | $375.35 – $665.36 (-25% / +33%) |
Analysts (28): buy, mean target $571.46 (+14%)
From its own volatility (29% a year), no drift assumed: what its swings allow, not a forecast.
Vertex Pharmaceuticals news · last two days
News lean: Bullish · 1 up · 0 down- 32h agoVertex Pharma stock: Citi keeps USD 585.00 target for Vertex Pharma stockAd Hoc News
- 37h agoIs Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?Zacks
- 45h agoVertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key FactsZacks
- 2d agoForget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone DisordersMotley Fool
- 2d agoWhat You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings ReleaseBarchart
- 2d agoGoldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653MT Newswires
- 2d agoThe largest acquisition in Vertex's historyThe Motley Fool
- 3d agoBofA cuts target for Vertex Pharmaceuticals stock to USD 667Ad Hoc News
- 3d agoVertex Pharmaceuticals Inc. stock outperforms competitors on strong trading dayMarketWatch
- 4d agoVertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitorsMarketWatch
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.